title: Successful resolution of pneumonia developed in a patient affected by Crohn's disease, rheumatoid arthritis, myasthenia gravis and recurrent uveitis during concomitant treatment with tumour necrosis factor alpha inhibitors and conventional immunosuppressive drugs.
abstract: Tumour necrosis factor alpha inhibitors, both infliximab and adalimumab, have been approved for the treatment of both rheumatoid arthritis and Crohn's disease. A slight increase in the risk of infections in patients receiving immunosuppressants and/or biological agents has been reported. Here, we present the case of a 68-year-old woman affected by Crohn's disease, myasthenia gravis, recurrent uveitis and rheumatoid arthritis who developed pneumonia during concomitant treatment with biological agents and conventional immunosuppressive drugs.
authors: Gastroenterology Unit, University of Rome Sapienza, Viale del Policlinico 155, 00161, Rome, Italy. erika.angelucci@yahoo.it
authors: Erika
authors: E
authors: Angelucci
authors: Monica
authors: M
authors: Cesarini
authors: Piero
authors: P
authors: Vernia
mesh_terms: D000368:Aged; D000658:Amoxicillin / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000009:adverse effects; D018501:Antirheumatic Agents / Q000009:adverse effects*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy / Q000276:immunology / Q000503:physiopathology; D001327:Autoimmune Diseases / Q000188:drug therapy* / Q000503:physiopathology; D001379:Azathioprine / Q000009:adverse effects; D019818:Clavulanic Acid / Q000627:therapeutic use; D003424:Crohn Disease / Q000188:drug therapy / Q000276:immunology / Q000503:physiopathology; D005260:Female; D006801:Humans; D016867:Immunocompromised Host / Q000187:drug effects*; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D000069285:Infliximab; D009157:Myasthenia Gravis / Q000188:drug therapy / Q000276:immunology / Q000503:physiopathology; D011014:Pneumonia / Q000188:drug therapy / Q000276:immunology*; D011239:Prednisolone / Q000009:adverse effects; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*; D014605:Uveitis / Q000188:drug therapy / Q000276:immunology / Q000503:physiopathology
chemical_list: D000900:Anti-Bacterial Agents; D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D007166:Immunosuppressive Agents; D014409:Tumor Necrosis Factor-alpha; D019818:Clavulanic Acid; D000658:Amoxicillin; D011239:Prednisolone; D000069285:Infliximab; D001379:Azathioprine